巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    vTv Therapeutics

    VTVT
    1.320
    0.000
    0.00%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・vTv Therapeutics - 延遲價格・最後更新於 18/08 8:28
    最高位
    --
    最低位
    --
    開市價
    --
    前收市價
    1.320
    成交量(千)
    --
    成交額(百萬)
    --
    買入
    0.995
    賣出
    1.490
    每手股數
    --
    市值(百萬)
    107.56
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    2.170 - 0.382
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    vTv Therapeutics
    證券代碼
    VTVT.US
    所屬板塊
    Biotechnology
    公司業務
    vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (TTP488), an orally administered drug. Its other products include TTP399, type II diabetes drug candidate. TTP399 is also an orally administered drug that targets the glucagon-like peptide-1 receptor. It also has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
    發行量
    80665764
    公司總部
    3980 Premier Drive, Suite 310
    公司網址
    https://www.vtvtherapeutics.com
    公司電郵
    IR@vtvtherapeutics.com
    公司電話
    +1 336 841-0300
    暫無內容

    關於

    vTv Therapeutics(VTVT.US)所屬的行業板塊為Biotechnology。
    vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (TTP488), an orally administered drug. Its other products include TTP399, type II diabetes drug candidate. TTP399 is also an orally administered drug that targets the glucagon-like peptide-1 receptor. It also has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
    詳細公司背景可參考: https://www.vtvtherapeutics.com